Global pharmaceutical companies including Indianapolis-based Eli Lilly and Co. are heading into smaller cities and rural areas to learn about the health care needs of about 70 percent of India’s population.
The Indianapolis-based drugmaker warned that a much-anticipated new drug for rheumatoid arthritis might be delayed another 18 months.
The deal is Eli Lilly and Co.’s latest push into a growing disease area for such disorders as arthritis, lupus and multiple sclerosis.
The grant from the Indianapolis-based philanthropic giant is aimed at bolstering Indiana’s stature as a life sciences research hub.
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
Eli Lilly and Co. announced the “strategic research collaboration” Thursday morning, calling it the largest agreement of its kind between Purdue and a single company.
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
America's three insulin manufacturers—Indianapolis-based Eli Lilly and Co., Sanofi and Novo Nordisk—would face fines of $5,000 daily if they fail to provide the data.
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
Rice, 52, who had been the company's top finance officer since 2006, is one of the most powerful black executives in corporate America. He had been widely considered a leading candidate to succeed CEO John Lechleiter, but that position went to fellow Lilly executive Dave Ricks.
Leigh Ann Pusey will join Eli Lilly and Co. next month as senior vice president for corporate affairs and communications.
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.
Oakland University in suburban Detroit on Thursday announced that its board of trustees unanimously chose Ora Hirsch Pescovitz for the job after a search involving more than 60 candidates.
The Indianapolis drugmaker is trying to reassure Wall Street that its pipeline is still poised to deliver.
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
The Indianapolis-based drugmaker beat Wall Street expectations by 2 cents a share—performance it attributed to brisk sales of new products.
Eli Lilly and Co. told a federal jury that a German company is trying to take credit for centuries-old Chinese medicine in seeking royalties on the use of its erectile-dysfunction drug Cialis to treat an enlarged prostate.
The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller.
